2021
Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study
Dwyer KE, Wang R, Cozen W, Cartmel B, Wiemels JL, Morimoto LM, Metayer C, Ma X. Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study. Cancer Epidemiology Biomarkers & Prevention 2021, 30: cebp.0535.2021. PMID: 34548330, DOI: 10.1158/1055-9965.epi-21-0535.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaT-cell non-Hodgkin lymphomaCase-control studyBirth characteristicsMode of deliveryYear of birthOdds ratioNHL riskUnconditional multivariable logistic regression modelsPopulation-based case-control studyCases of NHLMultivariable logistic regression modelConfidence intervalsAge of diagnosisPediatric Burkitt lymphomaLogistic regression modelsCesarean sectionHistologic subtypeDecreased riskHodgkin's lymphomaMaternal ageBurkitt's lymphomaElevated riskLower riskMaternal education
2019
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Journal Of The National Comprehensive Cancer Network 2019, 17: 1194-1202. PMID: 31590152, DOI: 10.6004/jnccn.2019.7314.Peer-Reviewed Original ResearchConceptsRituximab discontinuationRituximab initiationHodgkin's lymphomaRelative riskPhysician experienceHigh-quality cancer careOlder adultsInitiation of rituximabEarly treatment discontinuationInfusion-related reactionsPopulation-based studySEER-Medicare dataNon-Hodgkin lymphomaModified Poisson regressionCancer treatment outcomesEarly discontinuationTreatment discontinuationAnticancer immunotherapyPhysician volumeCancer careImproved outcomesOncologists' experiencesTreatment outcomesDiscontinuationRituximab
2017
Physician volume and discontinuation of rituximab during lymphoma treatment.
Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly discontinuationRituximab discontinuationPhysician volumeProvider volumeEnd Results-Medicare dataB-cell non-Hodgkin lymphomaCell non-Hodgkin lymphomaCox proportional hazards modelDiscontinuation of rituximabSevere infusion reactionsRetrospective cohort studyImpact of discontinuationDays of initiationProportional hazards modelDose-dependent mannerRituximab cyclesRituximab initiationInfusion reactionsOverall survivalCohort studyPrimary outcomeSystemic treatmentLymphoma treatmentRelative risk
2008
Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut Women
Wang R, Zhang Y, Lan Q, Holford TR, Leaderer B, Zahm SH, Boyle P, Dosemeci M, Rothman N, Zhu Y, Qin Q, Zheng T. Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut Women. American Journal Of Epidemiology 2008, 169: 176-185. PMID: 19056833, PMCID: PMC2727253, DOI: 10.1093/aje/kwn300.Peer-Reviewed Original ResearchConceptsRisk of NHLNon-Hodgkin lymphomaOccupational exposureConnecticut womenPopulation-based case-control studyOverall non-Hodgkin lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaCase-control studyB-cell lymphomaJob-exposure matrixIncident casesNHL subtypesBenzene exposureLymphomaRisk patternsWomenRiskExposureCarbon tetrachlorideAssociationBorderlineWork settingsLevelsStrong evidencePersonal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin Lymphoma
Zhang Y, De Sanjose S, Bracci PM, Morton LM, Wang R, Brennan P, Hartge P, Boffetta P, Becker N, Maynadie M, Foretova L, Cocco P, Staines A, Holford T, Holly EA, Nieters A, Benavente Y, Bernstein L, Zahm SH, Zheng T. Personal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin Lymphoma. American Journal Of Epidemiology 2008, 167: 1321-1331. PMID: 18408225, PMCID: PMC4025953, DOI: 10.1093/aje/kwn058.Peer-Reviewed Original ResearchConceptsRisk of FLNon-Hodgkin lymphomaHair dye usePersonal hair dye useCLL/SLLFollicular lymphomaHair dyesNHL subtypesChronic lymphocytic leukemia/small lymphocytic lymphomaRisk of NHLSmall lymphocytic lymphomaLymphocytic lymphomaNHL casesCertain subtypesLymphomaFL riskWomenSubtypesRiskPrevious studiesPersonal use
2007
Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma
Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP, Qin Q, Kilfoy B, Han J, Zheng T. Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma. American Journal Of Epidemiology 2007, 165: 1255-1264. PMID: 17327216, DOI: 10.1093/aje/kwm020.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaLymphoma subtypesNon-Hodgkin lymphomaCase-control studyHodgkin lymphoma subtypesUltraviolet radiation exposureHighest tertileConnecticut womenSun exposureLymphomaRadiation exposureDuration of timeWomenSuntanRiskFurther investigationDurationExposureTertileYearsSubtypesMonthsFamily history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma
Zhang Y, Wang R, Holford TR, Leaderer B, Zahm SH, Boyle P, Zhu Y, Qin Q, Zheng T. Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma. Cancer Causes & Control 2007, 18: 351-359. PMID: 17206533, DOI: 10.1007/s10552-006-0088-5.Peer-Reviewed Original ResearchConceptsRisk of NHLNon-Hodgkin lymphomaFirst-degree relativesNon-hematopoietic malignanciesFamily historyNHL subtypesPopulation-based case-control studyUnconditional logistic regressionCase-control studyFamily cancer historyNHL overallIncident casesCancer historyConclusionsThe riskConnecticut womenMalignancyLymphomaLogistic regressionHematopoietic malignanciesLeukemiaWomenRiskSubtypesSiblingsCervix